Hong Kong · Delayed Price · Currency is HKD ShockWave Medical Statistics
Total Valuation
WuXi Biologics has a market cap or net worth of HKD 128.67 billion. The enterprise value is 126.42 billion.
| Market Cap | 128.67B |
| Enterprise Value | 126.42B |
Important Dates
The next estimated earnings date is Wednesday, August 20, 2025.
| Earnings Date | Aug 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
WuXi Biologics has 4.07 billion shares outstanding. The number of shares has decreased by -2.80% in one year.
| Current Share Class | 4.07B |
| Shares Outstanding | 4.07B |
| Shares Change (YoY) | -2.80% |
| Shares Change (QoQ) | -1.35% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 36.94% |
| Float | 3.55B |
Valuation Ratios
The trailing PE ratio is 37.87 and the forward PE ratio is 26.38. WuXi Biologics's PEG ratio is 1.62.
| PE Ratio | 37.87 |
| Forward PE | 26.38 |
| PS Ratio | 6.47 |
| PB Ratio | 2.66 |
| P/TBV Ratio | 3.03 |
| P/FCF Ratio | 93.90 |
| P/OCF Ratio | 23.17 |
| PEG Ratio | 1.62 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.73, with an EV/FCF ratio of 92.26.
| EV / Earnings | 35.40 |
| EV / Sales | 6.36 |
| EV / EBITDA | 19.73 |
| EV / EBIT | 25.91 |
| EV / FCF | 92.26 |
Financial Position
The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.73 |
| Quick Ratio | 1.98 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.82 |
| Debt / FCF | 3.84 |
| Interest Coverage | 29.10 |
Financial Efficiency
Return on equity (ROE) is 8.82% and return on invested capital (ROIC) is 5.79%.
| Return on Equity (ROE) | 8.82% |
| Return on Assets (ROA) | 5.05% |
| Return on Invested Capital (ROIC) | 5.79% |
| Return on Capital Employed (ROCE) | 9.48% |
| Revenue Per Employee | 1.58M |
| Profits Per Employee | 284,012 |
| Employee Count | 12,575 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 6.71 |
Taxes
In the past 12 months, WuXi Biologics has paid 946.08 million in taxes.
| Income Tax | 946.08M |
| Effective Tax Rate | 18.39% |
Stock Price Statistics
The stock price has increased by +184.87% in the last 52 weeks. The beta is 0.50, so WuXi Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | +184.87% |
| 50-Day Moving Average | 27.16 |
| 200-Day Moving Average | 21.91 |
| Relative Strength Index (RSI) | 63.22 |
| Average Volume (20 Days) | 58,485,527 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WuXi Biologics had revenue of HKD 19.87 billion and earned 3.57 billion in profits. Earnings per share was 0.83.
| Revenue | 19.87B |
| Gross Profit | 8.14B |
| Operating Income | 4.88B |
| Pretax Income | 5.14B |
| Net Income | 3.57B |
| EBITDA | 6.22B |
| EBIT | 4.88B |
| Earnings Per Share (EPS) | 0.83 |
Balance Sheet
The company has 11.40 billion in cash and 5.26 billion in debt, giving a net cash position of 6.14 billion or 1.51 per share.
| Cash & Cash Equivalents | 11.40B |
| Total Debt | 5.26B |
| Net Cash | 6.14B |
| Net Cash Per Share | 1.51 |
| Equity (Book Value) | 48.40B |
| Book Value Per Share | 10.84 |
| Working Capital | 15.91B |
Cash Flow
In the last 12 months, operating cash flow was 5.55 billion and capital expenditures -4.18 billion, giving a free cash flow of 1.37 billion.
| Operating Cash Flow | 5.55B |
| Capital Expenditures | -4.18B |
| Free Cash Flow | 1.37B |
| FCF Per Share | 0.34 |
Margins
Gross margin is 40.97%, with operating and profit margins of 24.55% and 17.97%.
| Gross Margin | 40.97% |
| Operating Margin | 24.55% |
| Pretax Margin | 25.89% |
| Profit Margin | 17.97% |
| EBITDA Margin | 31.32% |
| EBIT Margin | 24.55% |
| FCF Margin | 6.89% |
Dividends & Yields
WuXi Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.80% |
| Shareholder Yield | n/a |
| Earnings Yield | 2.78% |
| FCF Yield | 1.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 16, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Nov 16, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
WuXi Biologics has an Altman Z-Score of 4.46 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.46 |
| Piotroski F-Score | 7 |